Focused On-demand Library for Meiosis-specific with OB domain-containing protein

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q8N635

UPID:
MEIOB_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8N635; B1AK39; C9J0S1; Q96RY0

BACKGROUND:
The Meiosis-specific with OB domain-containing protein is indispensable for homologous recombination in meiosis I, playing a key role in DSBs repair, crossover formation, and synapsis completion. It ensures the stabilization of recombinases like RAD51 and DMC1, crucial for effective homology search and meiotic recombination, showcasing its vital role in the genetic integrity of gametes.

THERAPEUTIC SIGNIFICANCE:
The protein's involvement in Spermatogenic failure 22, an infertility disorder stemming from spermatogenesis defects, underscores its potential as a therapeutic target. Exploring the function of the Meiosis-specific with OB domain-containing protein could lead to innovative treatments for infertility, highlighting the importance of research in this area.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.